Headquartered in The Sharp Building, Dublin Fiscal year ends December NYSE: PRGO perrigo.com
Perrigo Company plc (NYSE: PRGO) provides consumer self-care products and over-the-counter (OTC) health and wellness solutions. These help consumers prevent or treat conditions that can be self-managed.
The company runs a dual model of scaled branded products and retailer store-brand OTC products in everyday categories. It reports through four segments:
- **Self Care:** Upper Respiratory, Pain & Sleep, Healthy Lifestyle (including store brand nicotine replacement) and Digestive Health (including store brand laxatives), plus contract manufacturing.
- **Specialty Care:** Women's Health brands such as ellaOne and Opill, and Skin Health brands such as Compeed, Jungle Formula and Mederma, along with store brand and contract-manufactured Minoxidil.
- **Infant Formula:** Store brand and contract infant formula.
- **All Other:** Includes the Oral Care category, which is under strategic review.
Perrigo sells primarily in the U.S. and Europe. It is executing its 'Three-S' plan and an Operational Enhancement Program, and has been simplifying its portfolio through divestitures, including the Dermacosmetics and Richard Bittner businesses. After the third quarter of 2026, it agreed to sell its Infant Formula business, which will be reported as discontinued operations, to sharpen its focus on higher-return consumer self-care categories. The company reports results on both an 'All In' and a 'Core' basis; Core excludes Infant Formula and previously announced divestitures. Updated
The earnings beat is mostly a 3.5% adjusted tax rate worth $0.10, and Perrigo cut full-year core adjusted EPS guidance to $2.15 to $2.35 from $2.25 to $2.55. Revenue fell on cautious retailer stocking ahead of cough and cold season, and the Infant Formula sale brings an impairment in Q4.
Investors love ultra-high-yield dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid total return. Total return includes interest, capital gains, dividends, and distributions realized over time.…
Thursday's top analyst upgrades and downgrades included Cheniere Energy, Constellation Energy, Coty, DraftKings, Enovix, Mondelez International, Oracle, Shopify, Southern Copper, Toast, Walmart and Workday.
Wednesday's top analyst upgrades and downgrades included Amazon.com, Boeing, Carlyle, Frontline, Olin, Perrigo, Rocket Companies, Starwood Property Trust, Transocean and WW.
Thursday's top analyst upgrades and downgrades included Anheuser-Busch, Fiserv, Foot Locker, Fox, Kohl's, Snowflake, Starbucks, Williams-Sonoma and Zscaler.
Friday's top analyst upgrades, downgrades and initiations included Apple, Canopy Growth, CrowdStrike, Delta Air Lines, Johnson & Johnson, Rio Tinto, Roku, Square, Tilray and Twilio.
The top analyst upgrades, downgrades and initiations seen on Tuesday included Best Buy, Chesapeake Energy, Comcast, Cree, EverQuote, KeyCorp, Lumentum, Nvidia, Vodafone and Xilinx.
Thursday was a down day for the broad U.S. markets. After coming off a very positive Wednesday, the markets gave some of their gains back in this session. Crude oil continued lower…
The top analyst upgrades, downgrades and other research calls from Friday include AMD, ADT, BP, Campbell Soup, Funko, Intel, Overstock.com. Perrigo.
Thursday was a mixed day for the broad U.S. markets. Crude oil took another small step back in the session. The S&P 500 sectors were more or less split down the middle.
Chris Lange The top analyst upgrades, downgrades and other research calls from Wednesday include Alkermes, Cigna, International Paper, Medtronic, Tesla and Western Digital.
The top analyst upgrades, downgrades and other research calls from Tuesday include Alcoa, Alphabet, BP, Epizyme, FirstEnergy, First Solar, KeyCorp, Nvidia and Vale.
Here are 10 top Ireland-based public companies with shares that are traded in the United States that may be worth putting on a watchlist.
The top analyst upgrades, downgrades and other research calls from Thursday include AMD, Caterpillar, Chipotle, eBay, Facebook, Microsoft, Sirius XM and Starbucks.
The top analyst upgrades, downgrades and other research calls from Friday include Boston Scientific, Ciena, GoDaddy, Kratos Defense, Lipocine, Repligen, Teladoc and Vodafone.
The top analyst upgrades, downgrades and other research calls from Friday include AMD, CVS Health, Disney, Fiat Chrysler, Kinross Gold, Kohl's and NVIDIA.
Perrigo Company plc (NYSE: PRGO) provides consumer self-care products and over-the-counter (OTC) health and wellness solutions. These help consumers prevent or treat conditions that can be self-managed.
24/7 Wall St.'s 12-month price target for PRGO is $19.64, rated Buy. The Wall Street consensus target is $18.00. PRGO price prediction →
